Angel News
Angel News
Angel News

Back to Homepage

4th June 2018

TxCell names Lonza as its CAR-Treg cellular product manufacturer


TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, and Lonza Pharma & Biotech, one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets, has announced entering into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation. 



Register now to read full story

In order to read the full story we need you to register with us, please click the link below:

Register Now

Add a comment:




Enter the characters in the image shown:

Back to Homepage